Enliven Therapeutics Inc.
13F holders, Q1 2025 (March 31)1holders
$0.00avg. 13F price*
At the end of Q1 2025, 1 institutions reported holding Enliven Therapeutics Inc. in their 13F filings. The largest holder was Acuta Capital Partners, LLC ($0).
- Company
- Enliven Therapeutics Inc.
- CUSIP
- 452CVR012
- Latest filing quarter
- Q1 2025
Total Exit/New Position Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
Ownership 1 holders
| Acuta Capital Partners, LLC | 0.00% | New | 115,805 | $0 |
"% of holder's portfolio" is ENLIVEN THERAPEUTICS INC's weight in each manager's 13F, not the share of Enliven Therapeutics Inc. the manager owns.